ライフサイエンスコーパス: MAPK

1 MAPK and TNF signaling pathways were the most significan

2 MAPK pathways regulate different responses yet can share

3 MAPK regulates myosin II activity, but after initial the

4 MAPK-activated RREB1 recruits TGF-beta-activated SMAD fa

5 RNP-6 acts through TIR-1/PMK-1/MAPK signaling to modulate immunity.

6 (ROS) and downstream phosphorylation of p-38 MAPK.

7 developmental exposures to 6-OH-BDE-47 and a MAPK inhibitor resulted in offspring displaying similarl

8 It is activated by a MAPK binding protein, Ssp2, upon completion of the meiot

9 expression, inflammatory cell accumulation, MAPK signaling, and cytokine expression.

10 Disruption of an immune-activated MAPK cascade, consisting of MEKK1, MKK1/2, and MPK4, tri

11 neutrophil FcepsilonR1 expression, activates MAPK signaling, and promotes IL6 production.

12 data support the hypothesis that activating MAPK pathway mutations enhance PI resistance by increasi

13 ntified the late endosomal/lysosomal adaptor MAPK and mTOR activator (LAMTOR) complex as an important

14 thways-in-cancer (including; focal adhesion, MAPK signaling, PI3K-Akt-mTOR signaling, p53 signaling,

15 validated that PIK3CA wild-type cells adopt MAPK-dependent circuitries in breast cancer cells and th

16 s newly identified DHT/mAR-SLC39A9/G(alphai)/MAPK/MMP9 signaling with small molecules mAR-SLC39A9-shR

17 co-receptor TSPAN12 at cell membranes in an MAPK/ERK kinase (MEK)/ERK-dependent manner.

18 d the pro-apoptotic activities of JNK1/2 and MAPK p38 signaling cascades while partially downregulate

19 affinity and stimulate FGFR1 activation and MAPK response.

20 ch as lipid metabolism pathway, PI3K/AKT and MAPK signaling pathways.

21 M (EpEX) binds EGFR, activating both AKT and MAPK signaling to inhibit forkhead transcription factor

22 ates at the intersection of the PI3K/Akt and MAPK/ERK pathways and dephosphorylates and inactivates p

23 upstream activator of both the PI3K/Akt and MAPK/ERK pathways in liver cancer cells, and Nqo1 ablati

24 simultaneous inhibition of the PI3K/Akt and MAPK/ERK pathways, suppressed the expression of glycolys

25 een implicated in the resistance to BRAF and MAPK/ERK kinase inhibitors.

26 y belongs to cellular functions (calcium and MAPK), phytohormones (auxin, gibberellins, abscisic acid

27 ults suggest that FgCdc25 modulates cAMP and MAPK signalling pathways and further regulates fungal de

28 ar cAMP, and enhanced activation of EPAC and MAPK.

29 metabolism, glycolysis/gluconeogenesis, and MAPK, PI3K-AKT, HIPPO and calcium signaling pathways.

30 ed gene expression involved in NF-kappaB and MAPK activation, as well as expression of genes involved

31 d that gene pathways including NF-kappaB and MAPK downstream of TLR2/6 are upregulated in mice with i

32 signaling, whereas in B cells, NF-kappaB and MAPK pathways were regulated by both BTK and IRAK4.

33 phorylation of proteins in the NF-kappaB and MAPK pathways, both known to regulate cytokine expressio

34 egulation of the intracellular NF-kappaB and MAPK signaling pathways.

35 Cs, IRAK4 positively regulated NF-kappaB and MAPK signaling, whereas in B cells, NF-kappaB and MAPK p

36 IRF pathway without affecting NF-kappaB and MAPK signalling, which indicates that ligand recognition

37 hosphorylates both MAPK/ERK kinase (MEK) and MAPK kinase 7 (MKK7).

38 n was detected mainly in spinal neurons, and MAPK/ERK kinase inhibitors significantly inhibited chron

39 lomas to carcinomas by elevating p38MAPK and MAPK/ERK signaling.

40 skin carcinogenesis by elevating p38MAPK and MAPK/ERK signaling.

41 ites with concomitant activation of PI3K and MAPK pathways.

42 to-oncogene Ser/Thr protein kinase (RAF) and MAPK/ERK kinase, indicating that MAP3K19 activates ERK v

43 signaling toward activation of EPAC-RAP1 and MAPK, ultimately modulating tumor growth.

44 and macrophages infiltration, and STAT3 and MAPK signaling in the liver.

45 receptors Neo1 and Unc5B co-regulate Wnt and MAPK pathways in both mouse and human ESCs.

46 he kinases Lyn and protein kinase C-beta and MAPKs MKK-3/6 and p38MAPK or to upregulate MEK-1/2 and E

47 Virion-associated MAPK/ERK-2-mediated phosphorylation of Vpx plays a criti

48 20-fold more potently than the p38alpha/beta MAPK inhibitor, SB202190, and abrogated cancer cell-indu

49 This binary switching between MAPK and PI3K signaling, modulated by EGFR palmitoylatio

50 turally delivered together with ACD, blocked MAPK activation through Rac1 and thus prevented ACD-indu

51 imulate neurogenesis is reversed by blocking MAPK.

52 dition of a potent MEK inhibitor that blocks MAPK signaling brings each oncogene-induced surfaceome b

53 nces translocation to the nucleus and boosts MAPK signaling in vitro and in vivo.

54 s a kinase that directly phosphorylates both MAPK/ERK kinase (MEK) and MAPK kinase 7 (MKK7).

55 f phenformin to enhance the efficacy of BRAF-MAPK kinase-extracellular signal-regulated kinase pathwa

56 Acquired BRAF/MAPK/extracellular signal-regulated kinase inhibitor res

57 nderstanding of the mechanisms controlled by MAPK pathway driving melanogenesis will help develop new

58 could be partially or completely rescued by MAPK inhibitors and drugs that promote collagen IV foldi

59 the protein, which can be phosphorylated by MAPKs.

60 APK module, composed of MKK3 and the clade-C MAPKs MPK1/2/7, is activated by wounding in a MKK4/5-ind

61 Axundead signaling, and independently of Cac/MAPK.

62 B and enhanced kinase activity and cellular MAPK signaling.

63 In conclusion, combined MAPK inhibition and anti-PD-L1 therapy may provide treat

64 e assays and by expressing WT or kinase-dead MAPK kinase kinase 19 (MAP3K19) in the HEK293T cell line

65 MI/R-induced activation of p38, a pro-death MAPK, without altering ERK and JNK.

66 To address this question, Cdc42p-dependent MAPK pathways were compared in the filamentous (Sigma127

67 h P32 by itself was devoid of any detectable MAPK signaling activities, C5aR2 agonism significantly d

68 ygen species (ROS) production and downstream MAPK stress signaling.

69 ion is not necessary but enhances downstream MAPK signaling.

70 able to induce the activation of downstream MAPK/ERK and PI3K/Akt signaling as well as the neurite o

71 g to increased phosphorylation of downstream MAPK/ERK kinase (MEK)/extracellular signal-regulated kin

72 tein kinase pathway (SAPK) and its effector, MAPK Sty1, downregulates CAR assembly in S. pombe when i

73 ate that sustained activation of endothelial MAPK causes NF-kappaB-dependent inflammatory stress resp

74 Here we tracked spatiotemporal ERK MAPK dynamics in human epidermal stem cells.

75 Our findings demonstrate that ERK MAPK signal fluctuations link kinase activity to stem ce

76 in vitro, is Rab11a-dependent, involves ERK-MAPK-signalling and is inhibited by antibodies against a

77 Disruption of DBT severely attenuates ERK/MAPK signaling, p53 activation, and apoptosis in melanoc

78 ne on protein phosphorylation, including ERK/MAPK-targets like gephyrin, and modulates the synaptic A

79 nd lag-3/sel-8, which encode homologs of ERK/MAPK and core components of the Notch-dependent transcri

80 The RAS-ERK/MAPK (RAS-extracellular signal-regulated kinase/mitogen-

81 proto-oncogenes ERK2, a component of the ERK/MAPK pathway, and VAV1, a guanine nucleotide exchange fa

82 o family GTPases that also activates the ERK/MAPK pathway.

83 Fgf-MAPK signaling underperforms in pgk1- / - mutants even w

84 c analyses demonstrate that in stigmas, five MAPK kinases (MKKs), MKK1/2/3/7/9 are required to transm

85 vated dually phosphorylated ERK (dpERK) from MAPK/ERK kinase (MEK), a kinase that phosphorylates ERK,

86 iated inhibition of activation of the fungal MAPK Cek1.

87 of cells and phosphorylation of the p38/HOG MAPK, Hog1.

88 R) pathway and independent of alterations in MAPK and NF-kappaB signaling.

89 3(-/-)sutures with a consequent imbalance in MAPK, Hedgehog signaling and RUNX2 expression.

90 med NleD, a metalloprotease that inactivates MAPKs by specifically cleaving their activation loop.

91 ated downstream of oncogenic Kras, including MAPK signaling.

92 ity of pivotal signaling pathways, including MAPK, JAK-STAT, and PI3K-Akt.

93 egulation of 101 gene transcripts, including MAPK (mitogen-activated protein kinase) signaling target

94 by multiple regulatory molecules, including MAPKs, in turn regulated by multiple phosphorylation cas

95 h upregulation of FGF3 or HBEGF or increased MAPK signaling through an activating V600E mutation in B

96 n could partially be attributed to increased MAPK pathway activation and thromboxane generation.

97 IRF5 was required for PRR-induced MAPK and NF-kappaB activation, which, in turn, regulated

98 by activating mTOR and STAT1 and inhibiting MAPK pathways, shifting the iTreg polarization in favor

99 Interestingly, MAPK/ERK-2 packaging defective SIV failed to promote the

100 Specifically targeting the intrafollicular MAPK-Shh axis may provide a promising strategy to manage

101 with an MSK1-dependent downregulation of key MAPK and plasticity-related genes, notably of EGR1/Zif26

102 ting member of the mitogen-activated kinase (MAPK) family and its regulation is poorly understood in

103 MADD, the mitogen-activated protein kinase (MAPK) activating death domain protein, regulates various

104 ophage p38 mitogen-activated protein kinase (MAPK) activity.

105 ivation of mitogen-activated protein kinase (MAPK) and AKT.

106 ression of mitogen-activated protein kinase (MAPK) and endothelial NO synthase (eNOS) in EA.hy926 cel

107 fered with mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase signaling but in dif

108 redundant mitogen-activated protein kinase (MAPK) cascade is required for maintaining stigma recepti

109 described mitogen-associated protein kinase (MAPK) cascade, mediates multiple cellular processes and

110 of Src and mitogen-activated protein kinase (MAPK) inhibitors, which reverses Type II priming, both p

111 Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a

112 t the host mitogen-activated protein kinase (MAPK) network to suppress host immune responses.

113 tment, and mitogen-activated protein kinase (MAPK) pathway activation.

114 difies the mitogen-activated protein kinase (MAPK) pathway by downregulating the phosphorylation of M

115 nts of the mitogen activated protein kinase (MAPK) pathway enhancing GFP(rare) expression.

116 on RAS and mitogen-activated protein kinase (MAPK) pathway inputs for the induction of EMTs(12-19).

117 additional mitogen-activated protein kinase (MAPK) pathway regulators is invaluable in aiding our und

118 by the p38 mitogen-activated protein kinase (MAPK) pathway responding to oxidative stress.

119 regulates mitogen-activated protein kinase (MAPK) pathways (mating, filamentous growth or fMAPK, and

120 downstream mitogen-activated protein kinase (MAPK) pathways.

121 ate p44/42 mitogen-activated protein kinase (MAPK) signaling are found in half of myeloma patients an

122 ts amplify mitogen-activated protein kinase (MAPK) signaling by dimerizing with and activating WT C-R

123 c) and the mitogen-activated protein kinase (MAPK) signaling cascade.

124 oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in

125 within the Mitogen Activated Protein Kinase (MAPK) signaling network that promote unpredictable pheno

126 ed through mitogen-activated protein kinase (MAPK) signaling or genetic alteration across human cance

127 STAT3) and mitogen-activated protein kinase (MAPK) signaling pathways in intestinal and hepatic cells

128 nal kinase mitogen-activated protein kinase (MAPK) signaling to elicit a robust proinflammatory respo

129 activates mitogen-activated protein kinase (MAPK) signaling, encompassing extracellular signal-regul

130 hesion and mitogen-activated protein kinase (MAPK) signaling.

131 vation and mitogen-activated protein kinase (MAPK) signaling.

132 Act1), p38 mitogen-activated protein kinase (MAPK), Jun NH2-terminal kinase (JNK), and nuclear factor

133 K1, and of mitogen-activated protein kinase (MAPK)- and nuclear factor kappaB-dependent induction of

134 eleased by mitogen-activated protein kinase (MAPK)-stimulated acetylation to promote increased occupa

135 (Akt) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signal

136 us work on mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) (MEK) bi

137 hibitor of mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) (MEK)

138 ylated by mitogen-activated protein kinases (MAPK) in their transactivation domains (TAD) at so-calle

139 (ERK1/2), mitogen-activated protein kinases (MAPK), leading to uncontrolled melanoma growth.

140 f clade-A mitogen-activated protein kinases (MAPKs) MPK3 and MPK6 by wounding depends on the upstream

141 lation by mitogen-activated protein kinases (MAPKs).

142 MKP5 active site and was predicted to limit MAPK binding.

143 cificity phosphatase 1 expression to mediate MAPK activation switching.

144 ction by altering G(alphai) protein-mediated MAPK/MMP9 intracellular signaling to increase nAR-negati

145 ed to biosynthesis of secondary metabolites, MAPK signaling, photosynthesis, starch and sucrose metab

146 nNOS enzymatic activity, activation of MK2 (MAPK-activated protein kinase 2) and cofilin, and signal

147 Notably, MAPK signaling enhanced trafficking activity of KPNA4 vi

148 ting NRAS mutations leading to activation of MAPK kinase (MEK) and extracellular signal-regulated kin

149 hlighting a potential role for activation of MAPK signaling in iMCD-TAFRO pathogenesis and a rational

150 ajor players in determining the amplitude of MAPK signaling in cells.

151 st in part, by impairing the MEK-ERK axis of MAPK signal transduction.

152 which might contribute to longer duration of MAPK pathway signaling in cancer cells.

153 of ELK1, a known transcriptional effector of MAPK signaling in melanoma cells.

154 Short-term inhibition of MAPK pathway also induced mechanosignaling associated wi

155 gradation and demonstrate how integration of MAPK from the pheromone pathway allows one to tune the c

156 egulation of p63, an unreported mechanism of MAPK inhibitor resistance in melanoma, can be abrogated

157 ies have shown that the temporal patterns of MAPK activity (i.e. signaling dynamics) differentially r

158 JPH203 inhibited phosphorylation of MAPK / Erk, AKT, p70S6K and 4EBP-1.

159 IL-17A, and IL-22-induced phosphorylation of MAPK and JAK-STAT pathways, and activation of the NF-kap

160 , we defined MAP3K19 as a novel regulator of MAPK signaling.

161 Although core regulators of MAPK pathways are well known, new pathway regulators con

162 even represent potentially new regulators of MAPK signaling (RRN6, CIN5, MRS6, KAR2, TFA1, RSC3, RGT2

163 ves activation of Galphai and suppression of MAPK signaling.

164 Treatment of MAPK inhibitor-resistant melanoma cells with MDM2 inhibi

165 ling is severely impaired, and activation of MAPKs and PI3K signaling pathways are delayed in P2-defi

166 (MKK6), which activates the p38 subfamily of MAPKs, we found that decaging active MKK6 in fibroblasts

167 ed that recruitment of p300 was dependent on MAPKs.

168 e that PKA maintains repressive control over MAPK signaling as well as a negative feedback on cAMP co

169 We show that PMK-1 (p38 MAPK) primes animals for encounters with hostile environ

170 and IL-6 expression dependent on Erk1/2, p38 MAPK and PI3K-Akt signaling pathway activation, thereby

171 gnaling pathways, including the SMAD2/3, p38 MAPK, NF-kappaB, and AKT cascades.

172 lammation by cis-regulating MAP3K4 via a p38 MAPK pathway.

173 ased levels of DNA damage, and activated p38 MAPK, both inducers of senescence.

174 its transcription, resulting in altered p38 MAPK signaling.

175 EGFR2 transphosphorylation at Y1214, and p38 MAPK activation, leading to reverse EC migration.

176 tion promoted casein kinase II (CK2) and p38 MAPK activation, production of diverse cytokines, and sh

177 ess the phosphorylation of JNK, ERK, and p38 MAPK signaling pathways.

178 HCC cells by regulating MKK6 binding and p38 MAPK signaling.

179 itochondrial reactive oxygen species and p38 MAPK-dependent upregulation of cyclin-dependent kinase i

180 on depends on protein kinase B (Akt) and p38 MAPK.

181 ed kinase 1 binding protein 1 (TAB1) and p38 MAPK.

182 This interaction is promoted by p38 MAPK activation initiated by TGFbeta.

183 ly, inhibition of TTP phosphorylation by p38 MAPK inhibitors and non-phosphorylatable TTP mutant decr

184 appa-dual-specificity phosphatase (DUSP)-p38 MAPK, indicating a negative feedback mechanism.

185 Moreover, Mtb LAM did not elicit p38 MAPK phosphorylation or endocytosis, although these proc

186 n experimental tool to further elucidate p38 MAPK regulation and as a potential therapeutic for endot

187 e pathway in gut stem cells and identify p38 MAPK as an anti-aging target downstream of mTORC1.

188 in endothelial function and increases in p38 MAPK phosphorylation.

189 tivation of downstream kinases including p38 MAPK and RB S838/T841 phosphorylation.

190 Anisomycin (Aniso) increased p38 MAPK phosphorylation and reduced endothelial-dependent r

191 Furthermore, co-inhibiting p38 MAPK and TNFalpha prior to or along with chemotherapy su

192 ance that could be rescued by inhibiting p38 MAPK.

193 experiments indicated that NiPp inhibits p38 MAPK.

194 kinase-1 (TAK1) activation and NF-kappaB/p38 MAPK signaling.

195 of p38 mitogen-activated protein kinase (p38 MAPK) and decreases in the phosphorylation of Niban, a p

196 nd absence of inhibitors of RIPK3, MLKL, p38 MAPK, PI3K, and FAP-alpha.

197 may represent an endogenous regulator of p38 MAPK activation.

198 (RA) after pharmacological activation of p38 MAPK and also in multiple clinically relevant injury mod

199 5 deficiency, resulting in activation of p38 MAPK and JNK.

200 g identified TAK1-mediated activation of p38 MAPK as the critical pathway driving conversion.

201 We further showed that the activation of p38 MAPK in high glucose condition interferes with Src-extra

202 REX1 deficiency induced enhancement of p38 MAPK signaling, leading to F-actin reorganization and ac

203 f tumor dormancy including activation of p38 MAPK, decrease in Erk signaling and inhibition of FOXM1

204 hese genes was regulated by FOXM1 and/or p38 MAPK.

205 d programmed neutrophil death was PI3K-, p38 MAPK-, and JNK-dependent and evoked anti-inflammatory cy

206 ata suggest the opportunity to repurpose p38 MAPK inhibitors for adjunct host directed therapies.

207 istically, we find the stress-responsive p38 MAPK-MK2 signaling pathway stabilizes ARE mRNAs by phosp

208 Targeting p38 MAPK or p53 prevents or rescues ISC and villus aging and

209 These data demonstrate that p38 MAPK and Niban signaling have a role in endothelial func

210 Previously we demonstrated that p38 MAPK inhibition abates axonal dysfunction and slows dege

211 rats of both sexes, we demonstrate that p38 MAPK is generally required downstream of non-ionotropic

212 ve effect of topical eye delivery of the p38 MAPK inhibitor BIRB 796 in three models of glaucoma (mic

213 AP3K4 regulates inflammation through the p38 MAPK signaling pathway.

214 DPH oxidase but requires, in addition to p38 MAPK and PI3K, a serine protease activity, whereby FAP-a

215 in human infant AECs is regulated by (a) p38-MAPK/NF-kB dependent mechanism; and (b) exposure to pro-

216 ntly, genes of the PUFA biosynthesis and p38-MAPK pathway are required for multiple paradigms of DR-m

217 Thus, our study shows that PUFAs and p38-MAPK pathway function downstream of DR to help communica

218 nfant airway epithelium are regulated by p38-MAPK and NF-kB signalling.

219 via JNK activation, while NF-kappaB and p38/MAPK inhibition did not affect RUNX1 expression.

220 The p38/MAPK pathway, involving NFAT5 and SGK1, regulated FoxP3

221 tified an inhibitor of MKP5 using a p38alpha MAPK-derived, phosphopeptide-based small-molecule screen

222 losure of type I 1/2 inhibitors for p38alpha MAPK demonstrated how the stabilization of the R-spine c

223 C2C12 myotubes without suppressing p38alpha MAPK-dependent myogenesis.

224 inhibitor that preferentially binds p38beta MAPK, inhibited p300 activation 20-fold more potently th

225 -like receptor 4 in skeletal muscle, p38beta MAPK phosphorylates Ser-12 on p300 to stimulate C/EBPbet

226 dings demonstrate that prevention of p38beta MAPK-mediated activation of p300 by the FDA-approved kin

227 Thus, p38beta MAPK is a central mediator and therapeutic target of can

228 Genetic and pharmacologic MAPK-ERK activation through DUSP6 inhibition leads to CI

229 rylated protein kinase B, and phosphorylated MAPK kinase), suggesting the complementarity of these tw

230 the NPY2 receptor (NPY2R), stimulating PI3K, MAPK, and NFAT activation.

231 ivate wild-type (WT) SHP2 in LLPS to promote MAPK activation.

232 f FGFR2 kinase activity in the canonical RAF/MAPK/ERK/RSK and PI3K/AKT/PDK/mTOR/S6K pathways are iden

233 Notably, inhibition of Raf/MAPK/extracellular signal-regulated kinase signaling dec

234 outys are negative regulators of the Ras/Raf/MAPK signaling pathway and involved in regulation of org

235 he optic vesicle through suppressing Ras/Raf/MAPK signaling pathway.

236 Finally, combined inhibition of the Raf/MAPK/extracellular signal-regulated kinase axis and eIF4

237 RASA1, a negative regulator of Ras-MAPK signaling, is essential for the development and mai

238 luding those for disorders affecting the RAS-MAPK cell-signaling pathway (known as RASopathies) (30%

239 e signaling from tyrosine kinases to the Ras-MAPK pathway.

240 the phosphatidylinositol 3-kinase/AKT-, RAS/MAPK-, and STAT5-signaling pathways.

241 miR, and its expression was regulated by RAS/MAPK signaling.

242 context of GPVI/ITAM pathways, including Ras/MAPK axis proteins (ie, KSR1, SOS1, STAT1, Hsp27).

243 he RAS-mitogen-activated protein kinase (RAS/MAPK) pathway yet show unexplained variability in their

244 MEK, a central component of the Ras/MAPK cascade, is mutated in human tumors and development

245 also often exhibited upregulation of the RAS/MAPK pathway.

246 By constitutively activating the Ras/MAPK-pathway via Ras(V12)-overexpression in the postmito

247 cal inhibition, we show that the PKC/RasGRP3/MAPK signaling branch is the essential component that dr

248 le CIC-DUX4 targets that negatively regulate MAPK-ERK signaling.

249 ctions for Rho GTPase adaptors in regulating MAPK pathways.

250 regulates an epidermal p38 stress-responsive MAPK pathway to promote larval development in C. elegans

251 gnaling pathways that contribute to a robust MAPK phosphorylation and cytokine expression in mouse ma

252 tor differentially blocked heme-induced ROS, MAPK phosphorylation, and cytokine production in macroph

253 We also demonstrate that a second MAPK module, composed of MKK3 and the clade-C MAPKs MPK1

254 CP1 and the subsequent activation of the SRC/MAPK pathway.

255 getable oncogenic mutations in the JAK/STAT, MAPK, MYC, and chromatin modification pathways.

256 of the mammalian PAK2 family, and the Ste11 MAPK as regulators of H4-S47 and H4-T30, respectively.

257 ed phosphorylation of ERK1/2, a pro-survival MAPK in DM and AMPK-DN mice.

258 MPK-independent activation of a pro-survival MAPK member in DM mice.

259 uitment was more dependent on NF-kappaB than MAPKs.

260 We conclude that MAPK pathway targeting therapies mechanically reprogram

261 ear import of viral genome and suggests that MAPK/ERK-2-mediated Vpx phosphorylation is important for

262 The MAPK pathway is often found to be highly activated in TN

263 The MAPK/ERK kinase MEK is a shared effector of the frequent

264 thesis that the EDN1-EDNR axis activates the MAPK-ERK signaling pathway that is vital to the cancer c

265 Mutations activating the MAPK pathway are found in more than 80% of patients with

266 cine-rich repeat (NLR) protein SUMM2 and the MAPK kinase kinase MEKK2.

267 f the transcription factor NF-kappaB and the MAPK p38.

268 ce to the BRAF inhibitor vemurafenib and the MAPK/ERK kinase inhibitor cobimetinib.

269 f the retina can be restored by blocking the MAPK signaling pathway through overexpression of DN-Ras

270 ice through immunoregulation by blunting the MAPK (ERK, JNK)-mediated priming signal of the NLRP3 inf

271 ered pathway was Wnt pathway followed by the MAPK pathway.

272 ations in the BRAF gene, a key player in the MAPK pathway, are described in multiple tumor types, inc

273 a downstream signaling target of BRAF in the MAPK pathway, was evaluated and demonstrated synergistic

274 Moreover, the MAPK cascade is activated and fine-tuned by the crosstal

275 Only inhibition of the MAPK branch but not the FAK branch synergizes with inhib

276 oonan syndrome, PTPN11, the last tier of the MAPK cascade joins the group of genes mutated in RASopat

277 ere, we investigated the contribution of the MAPK module MEK5-ERK5 to SCLC growth.

278 a rationale for exploring inhibition of the MAPK pathway as a therapy for iMCD-TAFRO.

279 as indicative of increased activation of the MAPK pathway.

280 er with MAP3K4, an upstream regulator of the MAPK signaling pathway, and regulates its transcription

281 se-4 (MAP4K4) is an "upstream" member of the MAPK superfamily that is implicated in human cardiac mus

282 d for the CAMTA3 phospho-null variant of the MAPK-modified sites, suggesting additional flg22-respons

283 the strong dependence of the oncogene on the MAPK pathway to propagate signaling.

284 also abolished in the absence of Pmk1p, the MAPK of the cell integrity pathway (CIP), leading to pre

285 Targeting the MAPK pathway by combined inhibition of BRAF and MEK has

286 Here, we demonstrate that the MAPK signaling pathway is a general switch to trans-regu

287 of FGFR1 by hypoxia was mediated through the MAPK pathway and attenuated induction of the proapoptoti

288 n increased the association of EGFR with the MAPK adaptor Grb2 and decreased that with p85.

289 We further show that this MAPK nexus converges on Exo70A1, a previously identified

290 Corin cause endothelial dysfunction through MAPK and eNOS signaling in DN.

291 abrogate acquired resistance of melanoma to MAPK inhibitor targeted therapy.

292 lines or patient-derived xenograft models to MAPK pathway inhibition.

293 ed the role of p63 in acquired resistance to MAPK inhibition and show that p63 isoforms are upregulat

294 pathway during acquisition of resistance to MAPK inhibitors.

295 n melanomas frequently develop resistance to MAPK/extracellular signal-regulated kinase kinase inhibi

296 ependent calcium signaling could not trigger MAPK activation.

297 cytium but functions in defense and is under MAPK regulation.

298 and MPK6 by wounding depends on the upstream MAPK kinases MKK4 and MKK5 but is independent of jasmoni

299 ulates ABCB1 stability and transcription via MAPK/ERK and p53.

300 ther pathways predominate including the Wnt, MAPK, the ribosome, proteasome, endocytosis and tight ju

301 Moreover, we identify the WNT, MAPK/RAS and PI3K pathways as good candidate targets for